{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:30:12Z","timestamp":1782981012091,"version":"3.54.5"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00393-021-01067-3","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T07:02:57Z","timestamp":1631257377000},"page":"743-754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Therapie von Lungenfibrosen bei rheumatischen Systemerkrankungen (neue Therapien)","Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)"],"prefix":"10.1007","volume":"80","author":[{"given":"Katharina","family":"Buschulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Hoffmann-Vold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rucsan\ufeffdra","family":"Dobrota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"H\u00f6ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Krause","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"1067_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3238\/arztebl.m2021.0018","volume":"5","author":"M Kreuter","year":"2021","unstructured":"Kreuter\u00a0M, Ladner\u00a0UM, Heussel\u00a0CP et\u00a0al (2021) The diagnosis and treatment of pulmonary fibrosis. Dtsch Arztebl Int 5:118. https:\/\/doi.org\/10.3238\/arztebl.m2021.0018","journal-title":"Dtsch Arztebl Int"},{"key":"1067_CR2","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1056\/NEJMra2005230","volume":"383","author":"M Wijsenbeek","year":"2020","unstructured":"Wijsenbeek\u00a0M, Cottin\u00a0V (2020) Spectrum of fibrotic lung diseases. N\u00a0Engl J Med 383:958\u2013968","journal-title":"N Engl J Med"},{"key":"1067_CR3","volume-title":"Seltene Lungenerkrankungen","author":"Kreuter","year":"2021","unstructured":"Kreuter et\u00a0al (2021) Pulmonale Manifestationen rheumatologischer Erkrankungen. In: Kreuter\u00a0M, Costabel\u00a0U, Kirsten\u00a0D, Herth\u00a0FJF (Hrsg) Seltene Lungenerkrankungen, 2.\u00a0Aufl. Springer, Berlin Heidelberg","edition":"2"},{"issue":"10","key":"1067_CR4","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1164\/rccm.201903-0486OC","volume":"200","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold\u00a0AM, Fretheim\u00a0H, Halse\u00a0AK et al (2019) Tracking impact of interstitial lung disease in systemic sclerosis in a\u00a0complete nationwide cohort. Am J Respir Crit Care Med 200(10):1258\u20131266. https:\/\/doi.org\/10.1164\/rccm.201903-0486OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"1067_CR5","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1002\/art.1780370903","volume":"37","author":"VD Steen","year":"1994","unstructured":"Steen\u00a0VD, Conte\u00a0C, Owens\u00a0GR, Medsger\u00a0TA Jr (1994) Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum 37(9):1283\u20131289. https:\/\/doi.org\/10.1002\/art.1780370903","journal-title":"Arthritis Rheum"},{"issue":"2","key":"1067_CR6","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1136\/annrheumdis-2020-217455","volume":"80","author":"AM Hoffmann-Vold","year":"2021","unstructured":"EUSTAR collaborators, Hoffmann-Vold\u00a0AM, Allanore\u00a0Y, Distler\u00a0O et al (2021) Progressive interstitial lung disease in patients with systemic sclerosis-associated interstitial lung disease in the EUSTAR database. Ann Rheum Dis 80(2):219\u2013227. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217455","journal-title":"Ann Rheum Dis"},{"key":"1067_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pulmoe.2020.01.004","author":"RP Oliveira","year":"2020","unstructured":"Oliveira\u00a0RP, Ribeiro\u00a0R, Melo\u00a0L, Grima\u00a0B, Oliveira\u00a0S, Alves\u00a0JD (2020) Connective tissue disease-associated interstitial lung disease. Pulmonology. https:\/\/doi.org\/10.1016\/j.pulmoe.2020.01.004","journal-title":"Pulmonology"},{"issue":"10","key":"1067_CR8","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/1744666X.2020.1668269","volume":"15","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Volkmann\u00a0ER, Hoffmann-Vold\u00a0AM, Maher\u00a0TM (2019) Current and future perspectives on management of systemic sclerosis-associated interstitial lung disease. Expert Rev Clin Immunol 15(10):1009\u20131017. https:\/\/doi.org\/10.1080\/1744666X.2020.1668269","journal-title":"Expert Rev Clin Immunol"},{"issue":"5","key":"1067_CR9","doi-asserted-by":"publisher","first-page":"1902026","DOI":"10.1183\/13993003.02026-2019","volume":"55","author":"O Distler","year":"2020","unstructured":"Distler\u00a0O, Assassi\u00a0S, Maher\u00a0TM et\u00a0al (2020) Predictors of progression in systemic sclerosis patients with interstitial lung disease. Eur Respir\u00a0J 55(5):1902026. https:\/\/doi.org\/10.1183\/13993003.02026-2019","journal-title":"Eur Respir J"},{"key":"1067_CR10","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1002\/art.40769","volume":"71","author":"A Fischer","year":"2019","unstructured":"Fischer\u00a0A, Strek\u00a0ME, Cottin\u00a0V et al (2019) Proceedings of the American College of Rheumatology\/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: a\u00a0multidisciplinary approach to address challenges and opportunities. Arthritis Rheumatol 71:182\u2013195. https:\/\/doi.org\/10.1002\/art.40769","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"1067_CR11","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semarthrit.2018.01.010","volume":"48","author":"JL Medlin","year":"2018","unstructured":"Medlin\u00a0JL, Hansen\u00a0KE, McCoy\u00a0SS, Bartels\u00a0CM (2018) Pulmonary manifestations in late versus early systemic lupus erythematosus: a systematic review and meta-analysis. Semin Arthritis Rheum 48(2):198\u2013204. https:\/\/doi.org\/10.1016\/j.semarthrit.2018.01.010","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"1067_CR12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1055\/s-0039-1685187","volume":"40","author":"T Barba","year":"2019","unstructured":"Barba\u00a0T, Mainbourg\u00a0S, Nasser\u00a0M, Lega\u00a0JC, Cottin\u00a0V (2019) Lung diseases in inflammatory myopathies. Semin Respir Crit Care Med 40(2):255\u2013270. https:\/\/doi.org\/10.1055\/s-0039-1685187","journal-title":"Semin Respir Crit Care Med"},{"issue":"8","key":"1067_CR13","first-page":"934","volume":"42","author":"H Li","year":"2017","unstructured":"Li\u00a0H, Xiong\u00a0Z, Liu\u00a0J, Li\u00a0Y, Zhou\u00a0B (2017) Manifestations of the connective tissue associated interstitial lung disease under high resolution computed tomography. Zhong Nan Da Xue Xue Bao Yi Xue Ban 42(8):934\u2013939","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"key":"1067_CR14","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1093\/rheumatology\/kez177","volume":"58","author":"AC Duarte","year":"2019","unstructured":"Duarte\u00a0AC, Porter\u00a0JC, Leandro\u00a0MJ (2019) The lung in a\u00a0cohort of rheumatoid arthritis patients-an overview of different types of involvement and treatment. Rheumatology 58:2031\u20132038. https:\/\/doi.org\/10.1093\/rheumatology\/kez177","journal-title":"Rheumatology"},{"key":"1067_CR15","first-page":"33","volume":"21","author":"A Suzuki","year":"1994","unstructured":"Suzuki\u00a0A, Ohosone\u00a0Y, Obana\u00a0M, Mita\u00a0S, Matsuoka\u00a0Y, Irimajiri\u00a0S, Fukuda\u00a0J (1994) Cause of death in 81 autopsied patients with rheumatoid arthritis. J\u00a0Rheumatol 21:33\u201336","journal-title":"J Rheumatol"},{"key":"1067_CR16","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","volume":"156","author":"E Gabbay","year":"1997","unstructured":"Gabbay\u00a0E, Tarala\u00a0R, Will\u00a0R et\u00a0al (1997) Interstitial lung disease in recent onset rheumatoid arthritis. Am J Respir Crit Care Med 156:528\u2013535","journal-title":"Am J Respir Crit Care Med"},{"key":"1067_CR17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/14397595.2018.1442170","volume":"29","author":"Y Ito","year":"2019","unstructured":"Ito\u00a0Y, Arita\u00a0M, Kumagai\u00a0S et al (2019) Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease. Mod Rheumatol 29:98\u2013104. https:\/\/doi.org\/10.1080\/14397595.2018.1442170","journal-title":"Mod Rheumatol"},{"issue":"12","key":"1067_CR18","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","volume":"54","author":"M Ramos-Casals","year":"2017","unstructured":"EULAR Sj\u00f6gren Syndrome Task Force, Ramos-Casals\u00a0M, Brito-Zer\u00f3n\u00a0P, Vitali\u00a0C et al (2017) Characterization of systemic disease in primary Sj\u00f6gren\u2019s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. Rheumatology 54(12):2230\u20132238. https:\/\/doi.org\/10.1093\/rheumatology\/kev200 (Erratum in: Rheumatology (Oxford). 56(7):1245.)","journal-title":"Rheumatology"},{"issue":"6","key":"1067_CR19","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1164\/rccm.200403-417OC","volume":"171","author":"I Ito","year":"2005","unstructured":"Ito\u00a0I, Nagai\u00a0S, Kitaichi\u00a0M, Nicholson\u00a0AG, Johkoh\u00a0T, Noma\u00a0S, Kim\u00a0DS, Handa\u00a0T, Izumi\u00a0T, Mishima\u00a0M (2005) Pulmonary manifestations of primary Sjogren\u2019s syndrome: a\u00a0clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 171(6):632\u2013638. https:\/\/doi.org\/10.1164\/rccm.200403-417OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"24","key":"1067_CR20","doi-asserted-by":"publisher","first-page":"e11003","DOI":"10.1097\/MD.0000000000011003","volume":"97","author":"H Gao","year":"2018","unstructured":"Gao\u00a0H, Zhang\u00a0XW, He\u00a0J, Zhang\u00a0J, An\u00a0Y, Sun\u00a0Y, Jia\u00a0RL, Li\u00a0SG, Zhang\u00a0LJ, Li\u00a0ZG (2018) Prevalence, risk factors, and prognosis of interstitial lung disease in a\u00a0large cohort of Chinese primary Sj\u00f6gren syndrome patients: A case-control study. Medicine 97(24):e11003. https:\/\/doi.org\/10.1097\/MD.0000000000011003","journal-title":"Medicine"},{"issue":"1","key":"1067_CR21","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.autrev.2016.09.017","volume":"16","author":"F Roca","year":"2017","unstructured":"Roca\u00a0F, Dominique\u00a0S, Schmidt\u00a0J et\u00a0al (2017) Interstitial lung disease in primary Sj\u00f6gren\u2019s syndrome. Autoimmun Rev 16(1):48\u201354. https:\/\/doi.org\/10.1016\/j.autrev.2016.09.017","journal-title":"Autoimmun Rev"},{"issue":"3","key":"1067_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccm.2016.04.009","volume":"37","author":"TS Panchabhai","year":"2016","unstructured":"Panchabhai\u00a0TS, Farver\u00a0C, Highland\u00a0KB (2016) Lymphocytic interstitial pneumonia. Clin Chest Med 37(3):463\u2013474. https:\/\/doi.org\/10.1016\/j.ccm.2016.04.009","journal-title":"Clin Chest Med"},{"key":"1067_CR23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2014.01.008","volume":"48\u201349","author":"C Tani","year":"2014","unstructured":"Tani\u00a0C, Carli\u00a0L, Vagnani\u00a0S et\u00a0al (2014) The diagnosis and classification of mixed connective tissue disease. J\u00a0Autoimmun 48\u201349:46\u201349","journal-title":"J Autoimmun"},{"key":"1067_CR24","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1136\/annrheumdis-2017-211138","volume":"76","author":"C Hyldgaard","year":"2017","unstructured":"Hyldgaard\u00a0C, Hilberg\u00a0O, Pedersen\u00a0AB et al (2017) A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality. Ann Rheum Dis 76:1700\u20131706","journal-title":"Ann Rheum Dis"},{"key":"1067_CR25","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12931-014-0154-6","volume":"15","author":"T Moua","year":"2014","unstructured":"Moua\u00a0T, Zamora Martinez\u00a0AC, Baqir\u00a0M, Vassallo\u00a0R, Limper\u00a0AH, Ryu\u00a0JH (2014) Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 15:154","journal-title":"Respir Res"},{"key":"1067_CR26","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1136\/ard.2006.066068","volume":"66","author":"VD Steen","year":"2007","unstructured":"Steen\u00a0VD, Medsger\u00a0TA (2007) Changes in causes of death in systemic sclerosis, 1972\u20132002. Ann Rheum Dis 66:940\u2013944","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"1067_CR27","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1093\/rheumatology\/key060","volume":"57","author":"S Sato","year":"2018","unstructured":"Sato\u00a0S, Masui\u00a0K, Nishina\u00a0N et al (2018) Initial predictors of poor survival in myositis-associated interstitial lung disease: a\u00a0multicentre cohort of 497\u00a0patients. Rheumatology 57(7):1212\u20131221. https:\/\/doi.org\/10.1093\/rheumatology\/key060","journal-title":"Rheumatology"},{"issue":"4","key":"1067_CR28","first-page":"648","volume":"36","author":"N Narula","year":"2018","unstructured":"Narula\u00a0N, Narula\u00a0T, Mira-Avendano\u00a0I et al (2018) Interstitial lung disease in patients with mixed connective tissue disease: pilot study on predictors of lung involvement. Clin Exp Rheumatol 36(4):648\u2013651","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"1067_CR29","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1186\/s12890-019-0960-1","volume":"19","author":"M Cao","year":"2019","unstructured":"Cao\u00a0M, Sheng\u00a0J, Cai\u00a0H et al (2019) Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a\u00a0population-based study. BMC Pulm Med 19(1):215. https:\/\/doi.org\/10.1186\/s12890-019-0960-1","journal-title":"BMC Pulm Med"},{"issue":"9","key":"1067_CR30","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1164\/rccm.202001-0057ED","volume":"201","author":"M Kreuter","year":"2020","unstructured":"Kreuter\u00a0M, Maher\u00a0TM (2020) Treatment of acute exacerbation of idiopathic pulmonary fibrosis. A call to arms. Am J Respir Crit Care Med 201(9):1030\u20131032. https:\/\/doi.org\/10.1164\/rccm.202001-0057ED","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1067_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu\u00a0G, Collard\u00a0HR, Egan\u00a0JJ et al (2011) An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183(6):788\u2013824. https:\/\/doi.org\/10.1164\/rccm.2009-040GL","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1067_CR32","doi-asserted-by":"publisher","first-page":"1901760","DOI":"10.1183\/13993003.01760-2019","volume":"55","author":"M Kreuter","year":"2020","unstructured":"Kreuter\u00a0M, Polke\u00a0M, Bendstrup\u00a0E et\u00a0al (2020) Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir\u00a0J 55(4):1901760. https:\/\/doi.org\/10.1183\/13993003.01760-2019","journal-title":"Eur Respir J"},{"issue":"9","key":"1067_CR33","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","volume":"8","author":"PM George","year":"2020","unstructured":"George\u00a0PM, Spagnolo\u00a0P, Kreuter\u00a0M et\u00a0al (2020) Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir Med 8(9):925\u2013934. https:\/\/doi.org\/10.1016\/S2213-2600(20)30355-6","journal-title":"Lancet Respir Med"},{"issue":"9842","key":"1067_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0140-6736(12)61079-4","volume":"380","author":"A Fischer","year":"2012","unstructured":"Fischer\u00a0A, du Bois\u00a0R (2012) Interstitial lung disease in connective tissue disorders. Lancet 380(9842):689\u2013698","journal-title":"Lancet"},{"key":"1067_CR35","doi-asserted-by":"publisher","first-page":"e71","DOI":"10.1016\/S2665-9913(19)30144-4","volume":"2","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold\u00a0AM, Maher\u00a0TM, Philpot\u00a0EE et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2:e71\u2013e83","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"1067_CR36","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1164\/rccm.201202-0320ST","volume":"185","author":"KC Meyer","year":"2012","unstructured":"American Thoracic Society Committee on BAL in Interstitial Lung Disease, Meyer\u00a0KC, Raghu\u00a0G, Wood\u00a0B et\u00a0al (2012) An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185(9):1004\u20131014. https:\/\/doi.org\/10.1164\/rccm.201202-0320ST","journal-title":"Am J Respir Crit Care Med"},{"issue":"117","key":"1067_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1183\/09059180.00005510","volume":"19","author":"AU Wells","year":"2010","unstructured":"Wells\u00a0AU (2010) The clinical utility of bronchoalveolar lavage in diffuse parenchymal lung disease. Eur Respir Rev 19(117):237\u2013241","journal-title":"Eur Respir Rev"},{"issue":"12","key":"1067_CR38","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1164\/rccm.2106012","volume":"165","author":"D Bouros","year":"2002","unstructured":"Bouros\u00a0D, Wells\u00a0AU, Nicholson\u00a0AG et\u00a0al (2002) Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 165(12):1581\u20131586","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"1067_CR39","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1164\/rccm.201809-1650OC","volume":"199","author":"DN O\u2019Dwyer","year":"2019","unstructured":"O\u2019Dwyer\u00a0DN, Ashley\u00a0SL, Gurczynski\u00a0SJ et\u00a0al (2019) Lung microbiota contribute to pulmonary inflammation and disease progression in pulmonary fibrosis. Am J Respir Crit Care Med 199(9):1127\u20131138. https:\/\/doi.org\/10.1164\/rccm.201809-1650OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"1067_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S2213-2600(19)30059-1","volume":"7","author":"G Raghu","year":"2019","unstructured":"Raghu\u00a0G, Flaherty\u00a0KR, Lederer\u00a0DJ et\u00a0al (2019) Use of a\u00a0molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a\u00a0prospective validation study. Lancet Respir Med 7(6):487\u2013496. https:\/\/doi.org\/10.1016\/S2213-2600(19)30059-1","journal-title":"Lancet Respir Med"},{"key":"1067_CR41","doi-asserted-by":"publisher","first-page":"e94775","DOI":"10.1371\/journal.pone.0094775","volume":"9","author":"M Kono","year":"2014","unstructured":"Kono\u00a0M, Nakamura\u00a0Y, Enomoto\u00a0N et\u00a0al (2014) Usual interstitial pneumonia preceding collagen vascular disease: a\u00a0retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. Plos One 9:e94775","journal-title":"Plos One"},{"key":"1067_CR42","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1183\/13993003.00150-2015","volume":"46","author":"A Fischer","year":"2015","unstructured":"Fischer\u00a0A, Antoniou\u00a0KM, Brown\u00a0KK et\u00a0al (2015) An official European Respiratory Society\/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir\u00a0J 46:976\u2013987","journal-title":"Eur Respir J"},{"key":"1067_CR43","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.rmed.2016.10.017","volume":"123","author":"K Ahmad","year":"2017","unstructured":"Ahmad\u00a0K, Barba\u00a0T, Gamondes\u00a0D et\u00a0al (2017) Interstitial pneumonia with autoimmune features: clinical, radiologic, and histological characteristics and outcome in a\u00a0series of 57\u00a0patients. Respir Med 123:56\u201362","journal-title":"Respir Med"},{"key":"1067_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.rmed.2016.09.002","volume":"119","author":"S Chartrand","year":"2016","unstructured":"Chartrand\u00a0S, Swigris\u00a0JJ, Stanchev\u00a0L et\u00a0al (2016) Clinical features and natural history of interstitial pneumonia with autoimmune features: a single center experience. Respir Med 119:150\u2013154","journal-title":"Respir Med"},{"issue":"6","key":"1067_CR45","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1183\/13993003.01565-2015","volume":"47","author":"JM Oldham","year":"2016","unstructured":"Oldham\u00a0JM, Adegunsoye\u00a0A, Valenzi\u00a0E et\u00a0al (2016) Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir\u00a0J 47(6):1767\u20131775","journal-title":"Eur Respir J"},{"key":"1067_CR46","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","volume":"66","author":"R Conway","year":"2014","unstructured":"Conway\u00a0R, Low\u00a0C, Coughlan\u00a0RJ, O\u2019Donnell\u00a0MJ, Carey\u00a0JJ (2014) Methotrexate and lung disease in rheumatoid arthritis: a\u00a0meta-analysis of randomized controlled trials. Arthritis Rheumatol 66:803\u2013812","journal-title":"Arthritis Rheumatol"},{"key":"1067_CR47","first-page":"18","volume-title":"Kompendium Rheumatologie","author":"V Somogyi","year":"2020","unstructured":"Somogyi\u00a0V, Krause\u00a0A, Distler\u00a0J, Kreuter\u00a0M (2020) Interstitielle Lungenerkrankung bei Kollagenosen, Myositiden und rheumatoider Arthritis. In: Kompendium Rheumatologie, S\u00a018\u201326"},{"issue":"1","key":"1067_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer\u00a0V, Rondaan\u00a0C, Elkayam\u00a0O et\u00a0al (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79(1):39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882","journal-title":"Ann Rheum Dis"},{"key":"1067_CR49","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","volume":"6","author":"D Visca","year":"2018","unstructured":"Visca\u00a0D, Mori\u00a0L, Tsipouri\u00a0V et al (2018) Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a\u00a0prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respir Med 6:759\u2013770","journal-title":"Lancet Respir Med"},{"issue":"12","key":"1067_CR50","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1055\/a-1252-1492","volume":"74","author":"P Haidl","year":"2020","unstructured":"Haidl\u00a0P, Jany\u00a0B, Geiseler\u00a0J et al (2020) Leitlinie zur Langzeit-Sauerstofftherapie [Guideline for Long-Term Oxygen Therapy\u2014S2k-Guideline Published by the German Respiratory Society]. Pneumologie 74(12):813\u2013841. https:\/\/doi.org\/10.1055\/a-1252-1492","journal-title":"Pneumologie"},{"key":"1067_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006322.pub3","author":"L Dowman","year":"2017","unstructured":"Dowman\u00a0L, Hill\u00a0CJ, Holland\u00a0AE (2017) Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD006322.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"1067_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/S2213-2600(17)30383-1","volume":"5","author":"M Kreuter","year":"2017","unstructured":"Kreuter\u00a0M, Bendstrup\u00a0E, Russell\u00a0AM et\u00a0al (2017) Palliative care in interstitial lung disease: living well. Lancet Respir Med 5:968\u2013980","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1067_CR53","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-020-01459-0","volume":"21","author":"AM Hoffmann-Vold","year":"2020","unstructured":"Hoffmann-Vold\u00a0AM, Allanore\u00a0Y, Bendstrup\u00a0E et al (2020) The need for a\u00a0holistic approach for SSc-ILD\u2014achievements and ambiguity in a\u00a0devastating disease. Respir Res 21(1):197. https:\/\/doi.org\/10.1186\/s12931-020-01459-0","journal-title":"Respir Res"},{"key":"1067_CR54","doi-asserted-by":"publisher","unstructured":"Krause A, Kreuter M Lungenmanifestationen rheumatischer Erkrankungen. PneumoNews. https:\/\/doi.org\/10.1007\/s15033-020-1895-1\/. Zugegriffen: 5. Jan. 2021","DOI":"10.1007\/s15033-020-1895-1\/"},{"key":"1067_CR55","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/MCP.0000000000000508","volume":"24","author":"V Kouranos","year":"2018","unstructured":"Kouranos\u00a0V, Miranda\u00a0G, Corte\u00a0TJ, Renzoni\u00a0EA (2018) New treatment paradigms for connective tissue disease-associated interstitial lung disease. Curr Opin Pulm Med 24:453\u2013460","journal-title":"Curr Opin Pulm Med"},{"key":"1067_CR56","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1007\/s10067-019-04557-7","volume":"38","author":"AC Duarte","year":"2019","unstructured":"Duarte\u00a0AC, Cordeiro\u00a0A, Fernandes\u00a0BM et al (2019) Rituximab in connective tissue disease-associated interstitial lung disease. Clin Rheumatol 38:2001\u20132009","journal-title":"Clin Rheumatol"},{"key":"1067_CR57","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.semarthrit.2017.12.012","volume":"48","author":"C Fern\u00e1ndez-D\u00edaz","year":"2018","unstructured":"Fern\u00e1ndez-D\u00edaz\u00a0C, Loricera\u00a0J, Casta\u00f1eda\u00a0S (2018) Abatacept in patients with rheumatoid arthritis and interstitial lung disease: a national multicenter study of 63\u00a0patients. Semin Arthritis Rheum 48:22\u201327","journal-title":"Semin Arthritis Rheum"},{"key":"1067_CR58","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna\u00a0D, Lin\u00a0CJF, Furst\u00a0DE et al (2020) A randomised placebo-controlled phase 3 trial of tocilizumab in systemic sclerosis. Lancet Respir Med 8:963\u2013974","journal-title":"Lancet Respir Med"},{"key":"1067_CR59","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1007\/s00393-018-0565-8","volume":"77","author":"J Hornig","year":"2018","unstructured":"Hornig\u00a0J, Weinhage\u00a0T, Schmidt\u00a0LH et\u00a0al (2018) Response of dermatomyositis with lung involvement to Janus kinase inhibitor treatment. Z\u00a0Rheumatol 77:952\u2013957. https:\/\/doi.org\/10.1007\/s00393-018-0565-8","journal-title":"Z Rheumatol"},{"key":"1067_CR60","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler\u00a0O, Highland\u00a0KB, Gahlemann\u00a0M et al (2019) Nintedanib for systemic sclerosis-associated interstitial lung disease. N\u00a0Engl J Med 380:2518\u20132528. https:\/\/doi.org\/10.1056\/NEJMoa1903076","journal-title":"N Engl J Med"},{"key":"1067_CR61","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","volume":"381","author":"KR Flaherty","year":"2019","unstructured":"Flaherty\u00a0KR, Wells\u00a0AU, Cottin\u00a0V et\u00a0al (2019) Nintedanib in progressive Fibrosing interstitial lung diseases. N\u00a0Engl J Med 381:1718\u20131727","journal-title":"N Engl J Med"},{"issue":"9","key":"1067_CR62","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna\u00a0D, Albera\u00a0C, Fischer\u00a0A et al (2016) An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J\u00a0Rheumatol 43(9):1672\u20131679. https:\/\/doi.org\/10.3899\/jrheum.151322","journal-title":"J Rheumatol"},{"issue":"3","key":"1067_CR63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3899\/jrheum.161040","volume":"45","author":"VM Hsu","year":"2018","unstructured":"Hsu\u00a0VM, Denton\u00a0CP, Domsic\u00a0RT et al (2018) Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. J\u00a0Rheumatol 45(3):405\u2013410","journal-title":"J Rheumatol"},{"issue":"7","key":"1067_CR64","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.tips.2012.04.002","volume":"33","author":"SL Goodman","year":"2012","unstructured":"Goodman\u00a0SL, Picard\u00a0M (2012) Integrins as therapeutic targets. Trends Pharmacol Sci 33(7):405\u2013412","journal-title":"Trends Pharmacol Sci"},{"key":"1067_CR65","doi-asserted-by":"publisher","first-page":"h6819","DOI":"10.1136\/bmj.h6819","volume":"352","author":"SC Mathai","year":"2016","unstructured":"Mathai\u00a0SC, Danoff\u00a0SK (2016) Management of interstitial lung disease associated with connective tissue disease. BMJ 352:h6819","journal-title":"BMJ"},{"key":"1067_CR66","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s10067-017-3707-5","volume":"36","author":"J Rojas-Serrano","year":"2017","unstructured":"Rojas-Serrano\u00a0J, Herrera-Bringas\u00a0D, P\u00e9rez-Rom\u00e1n\u00a0DI et al (2017) Rheumatoid arthritis-related interstitial lung disease (RA-ILD): methotrexate and the severity of lung disease are associated to prognosis. Clin Rheumatol 36:1493\u20131500","journal-title":"Clin Rheumatol"},{"key":"1067_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjopen-2018-028466","volume":"9","author":"P Kiely","year":"2019","unstructured":"Kiely\u00a0P, Busby\u00a0AD, Nikiphorou\u00a0E et\u00a0al (2019) Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a\u00a0multivariate analysis in the ERAS and ERAN inception cohorts. Bmj Open 9:1\u201312","journal-title":"Bmj Open"},{"key":"1067_CR68","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1080\/03007995.2019.1647040","volume":"35","author":"M Wijsenbeek","year":"2019","unstructured":"Wijsenbeek\u00a0M, Kreuter\u00a0M, Olson\u00a0A et\u00a0al (2019) Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 35:2015\u20132024","journal-title":"Curr Med Res Opin"},{"key":"1067_CR69","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin\u00a0DP, Roth\u00a0MD, Clements\u00a0PJ et al (2016) Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a\u00a0randomised controlled, double-blind, parallel group trial. Lancet Respir Med 4:708\u2013719","journal-title":"Lancet Respir Med"},{"key":"1067_CR70","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","volume":"354","author":"DP Tashkin","year":"2006","unstructured":"Tashkin\u00a0DP, Elashoff\u00a0R, Clements\u00a0PJ et\u00a0al (2006) Cyclophosphamide versus placebo in scleroderma lung disease. N\u00a0Engl J Med 354:2655\u20132666","journal-title":"N Engl J Med"},{"issue":"2","key":"1067_CR71","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1093\/rheumatology\/keaa675","volume":"60","author":"M Hughes","year":"2021","unstructured":"Hughes\u00a0M, Denton\u00a0CP, Khanna\u00a0D (2021) Rituximab for the treatment of systemic sclerosis-interstitial lung disease. Rheumatology 60(2):489\u2013491. https:\/\/doi.org\/10.1093\/rheumatology\/keaa675","journal-title":"Rheumatology"},{"issue":"1","key":"1067_CR72","doi-asserted-by":"publisher","first-page":"e000826","DOI":"10.1136\/rmdopen-2018-000826","volume":"5","author":"AM Hoffmann-Vold","year":"2019","unstructured":"Hoffmann-Vold\u00a0AM, Distler\u00a0O, Murray\u00a0B et al (2019) Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a\u00a0Delphi-based expert consensus on core clinical features. RMD Open 5(1):e826. https:\/\/doi.org\/10.1136\/rmdopen-2018-000826","journal-title":"RMD Open"},{"key":"1067_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/art.41668","author":"D Roofeh","year":"2021","unstructured":"Roofeh\u00a0D, Lin\u00a0CJF, Khanna\u00a0D et\u00a0al (2021) focuSSced investigators. Tocilizumab prevents progression of early systemic sclerosis associated interstitial lung disease. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41668","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"1067_CR74","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3899\/jrheum.150844","volume":"43","author":"J Bauhammer","year":"2016","unstructured":"Bauhammer\u00a0J, Blank\u00a0N, Fiehn\u00a0C et al (2016) Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a\u00a0marker for severity and treatment response. J\u00a0Rheumatol 43(8):1566\u20131574. https:\/\/doi.org\/10.3899\/jrheum.150844","journal-title":"J Rheumatol"},{"key":"1067_CR75","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","volume":"18","author":"T Barba","year":"2019","unstructured":"Barba\u00a0T, Fort\u00a0R, Cottin\u00a0V et al (2019) Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis. Autoimmun Rev 18:113\u2013122. https:\/\/doi.org\/10.1016\/j.autrev.2018.07.013","journal-title":"Autoimmun Rev"},{"key":"1067_CR76","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1056\/NEJMc1900045","volume":"381","author":"Z Chen","year":"2019","unstructured":"Chen\u00a0Z, Wang\u00a0X, Ye\u00a0S (2019) Tofacitinib in amyopathic dermatomyositis\u2014associated interstitial lung disease. N\u00a0Engl J Med 381:291\u2013293","journal-title":"N Engl J Med"},{"key":"1067_CR77","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.ccm.2019.05.012","volume":"40","author":"GE Thompson","year":"2019","unstructured":"Thompson\u00a0GE, Specks\u00a0U (2019) Update on the management of respiratory manifestations of the antineutrophil cytoplasmic antibodies-associated vasculitides. Clin Chest Med 40:573\u2013582. https:\/\/doi.org\/10.1016\/j.ccm.2019.05.012","journal-title":"Clin Chest Med"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01067-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-021-01067-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-021-01067-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T16:46:40Z","timestamp":1633711600000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-021-01067-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":77,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1067"],"URL":"https:\/\/doi.org\/10.1007\/s00393-021-01067-3","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"30 July 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>K.\u00a0Buschulte<\/b>: A.\u00a0Finanzielle Interessen: gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Mitarbeiter der Thoraxklinik, Universit\u00e4tsklinikum Heidelberg.<b> A.-M.\u00a0Hoffmann-Vold<\/b>: A.\u00a0Finanzielle Interessen: Unabh\u00e4ngige Forschungsf\u00f6rderung von Boehringer Ingelheim an eigene Institution.\u00a0\u2013 Erstattung der Reise- und \u00dcbernachtungskosten: Actelion, Boehringer-Ingelheim.\u00a0\u2013 Beratungen: Actelion, Arxx Therapeutics, Boehringer Ingelheim, Lilly, Medscape, Merck Sharp & Dohme, Roche.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin, Universit\u00e4tsklinik Oslo, Norwegen | Mitgliedschaft: EULAR.<b> R.\u00a0Dobrota<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung: Actelion, Pfizer.\u00a0\u2013 Referentenhonorar: Actelion, partielle Kostenerstattung von Kongressteilnahmegeb\u00fchren: IBSA, Pfizer, Actelion, Roche.\u00a0\u2013 Teilnahme bei ILD Advisory board von Boehringer Ingelheim.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin, Rheumatologie, Klinik f\u00fcr Rheumatologie, Universit\u00e4tsspital Z\u00fcrich.<b> P.\u00a0H\u00f6ger<\/b>: A.\u00a0Finanzielle Interessen: gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Assistenzarzt, Pneumologie und Beatmungsmedizin, Thoraxklinik, Universit\u00e4tsklinikum Heidelberg.<b> A.\u00a0Krause<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: AbbVie (finanziell).\u00a0\u2013 Honorare f\u00fcr Vortragst\u00e4tigkeit und Kostenerstattungen f\u00fcr Kongressbesuche: AbbVie, Berlin-Chemie, BMS, Boehringer Ingelheim, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB.\u00a0\u2013 Honorare f\u00fcr Beratert\u00e4tigkeit: AbbVie, BMS, Boehringer Ingelheim, Janssen, Lilly, MSD, Mylan, Novartis, Pfizer, Roche.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Chefarzt der Abteilung f\u00fcr Rheumatologie, klinische Immunologie und Osteologie des Immanuel Krankenhauses Berlin | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Rheumatologie (Pr\u00e4sident), Rheuma-Akademie, Verband Rheumatologischer Akutkliniken, Berufsverband Deutscher Rheumatologen, Deutsche Rheuma-Liga, Deutsche Vereinigung Morbus Bechterew.<b> M.\u00a0Kreuter<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung (eigenes Institut): Boehringer, Roche.\u00a0\u2013 Berater und Schulungsreferent: Boehringer, Roche.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Mitarbeiter der Thoraxklinik, Universit\u00e4tsklinikum Heidelberg | Mitgliedschaften: DGP (Sektionssprecher), ERS (group chair).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}